Overall, these data indicate that acquired HER2 mutations account for cross resistance in i) HER2+ BC patients treated with HER2-targeting agents, where they are potentially useful biomarkers of trastuzumab/lapatinib resistance in subsequent lines of treatments; ii) HER2- BC patients treated with endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.